海洋衍生聚合物-多糖为动脉样性心血管疾病的有前途的自然疗法
在PubMed上查看摘要
概括
此摘要是机器生成的。通过向炎症和脂质,海洋衍生的多糖具有治疗动脉样性心血管疾病 (ASCVD) 的潜力. 需要进一步的人体研究来证实它们在ASCVD的预防和治疗中的安全性和有效性.
科学领域
- 海洋生物技术
- 心血管药理学
- 自然产品化学
背景情况
- 动脉样性心血管疾病 (ASCVD) 是一个主要的全球健康负担,由脂质障碍,炎症,氧化应激和内皮功能障碍驱动.
- 像他类药物这样的当前疗法存在局限性, 需要针对残留心血管风险的新型多重目标治疗.
- 海洋衍生多糖 (MDP) 具有与ASCVD病理相关的多种生物活性.
研究的目的
- 批判性地审查ASCVD的MDP临床前和临床证据.
- 探索MDP的药理动力学,作用机制和治疗潜力.
- 确定转化方面的挑战,并提出MDP临床应用的战略.
主要方法
- 全面的文献搜索和对MDPs (富可,阿尔吉纳特,拉米纳林,卡拉,奇托桑) 的现有研究的综合.
- 临床前数据 (体外和动物研究) 和新出现的临床证据的分析.
- 评估MDPs的抗炎,抗氧化,脂质调节,抗血栓和内皮保护作用.
主要成果
- 在ASCVD中,MDP表现出有希望的抗炎,抗氧化,降脂,抗血栓和内皮保护性质.
- 临床前数据表明治疗潜力,但临床证据仍然有限.
- 主要挑战包括结构变异性,口服生物可用性差以及人体数据不足.
结论
- 由于其多重向的生物活性,MDP对ASCVD的预防和治疗具有前途的自然疗法.
- 通过新的传递系统克服标准化和生物可用性等挑战至关重要.
- 严格,精心设计的人体临床试验是有必要的,以验证MDPs在ASCVD治疗中的疗效和安全性.
相关概念视频
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
The word polymer is derived from the Greek words “poly” which means “many” and “mer” which means “parts”. Polymers are long chains of molecules composed of repeating units of smaller molecules, known as monomers. They either occur naturally, such as DNA and proteins, or can be constructed synthetically, like plastics. They have varied structural characteristics, such as linear chains, branched chains, or complex networks, that contribute to the...
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

